There are a number of translational funding opportunities available to UCL and partner researchers internally and externally. The TRO helps PIs identify the most suitable scheme for their project.
These funds differ from standard project grants by being milestone driven with clear go/no go decision criteria which require active project management.
Internal (proof-of-concept) funding opportunities
- UCL Therapeutic Acceleration Support (TAS) Fund
- Biomedical Research Centre (BRC) Fund
- EPSRC Impact Acceleration Award Funding
- Internal Venture Funding (from the UCL Technology Fund and the Apollo Fund)
External funding opportunities
- MRC Developmental Pathway Funding Scheme (DPFS)
- NIHR Invention for Innovation (i4i) Scheme
- Charity Schemes (Wellcome, LifeArc, BHF)
- Industry Partnerships
- Collaboration Opportunity: Ono's Project to support rising star scientists - OPEN (18th December deadline)
Ono Pharmaceutical Co., Ltd. is a middle sized Japanese Pharmaceutical company having its history about 300 years. The company is in active pursuit of the discovery and development of drugs that meet the unmet medical needs at the frontline of healthcare not only by its in-house research but also by collaborations with academic institutions having innovative idea and cutting-edge technologies.
Following two successful rounds of the rising star initiative, The Company is actively seeking opportunities to launch further research collaborations with UCL and has available seed funding to support a short exploratory collaborative research project. Follow-on funding may be available for larger collaborations should the company find such continued funding productive through the initial project.
The call is open to researchers above (and including) Grade 8 but below Professorial level.
Budget, study period
• Budget: 30,000 – 70,000 GBP depends on research proposals
• Study period: From 6 months to 1 year
Areas of interest
Please only apply within the areas of interest listed below. Keywords are listed to give some idea of specific areas of interest but Ono will accept applications for research outside keywords (but within areas of interest)
- Submission Deadline: 18th December 2019
- Industrial Connectivity Awards - NOW CLOSED
UCL TRO invites members of the UCL community to apply for funding under the Proximity-to-Discovery award which was granted to the TRO from the MRC. The Industry Connectivity Awards are suitable for UCL researchers looking to promote their engagement with industry.
- Therapeutic Accelerations Support (TAS) Fund - Call 6 - NOW CLOSED
Deadline for Applications: Friday 11th October 2019, 5pm
The UCL Therapeutic Acceleration Support (TAS) Fund is supported by the MRC Confidence in Concept scheme, Wellcome Trust Institutional Strategic Support Fund and the three Biomedical Research Centres (BRC) affiliated with UCL - University College London Hospitals NHS Foundation Trust (UCLH) BRC, Great Ormond Street Hospital (GOSH) BRC and Moorfields BRC.
It aims to accelerate the transition from discovery science to the early stages of therapeutic development by providing responsive and flexible funding to support preliminary translational work.
The scheme expects to typically fund individual projects in the range of £60-75K (directly incurred costs only) for up to 12 months.
A list of previous TAS fund awarded projects can be found here.
Remit of this Call
All modalities of therapy and diagnostics including engineering/medical technology and bioinformatics approaches can be submitted for consideration. Applications from across the breadth of diseases researched in UCL and its partner hospitals will be welcomed.
Enquiries about the scheme should be addressed to Dr Simon Eaglestone (email@example.com) in the Translational Research Office.
- Submission Deadline = 15th September 2019
- Funding decision = Within 4 weeks of submission
- Proposed project start date = Projects must be completed by 31st March 2020 (no extensions possible)
For additional information, details on how to apply to download an application form, please click here.